cancer breast overview dr. ehab m.oraby. introduction breast is a modified sweat gland between skin...

CANCER BREAST OVERVIEW

Dr. Ehab M.Oraby

INTRODUCTION

Breast is a modified sweat gland between skin and pectoral fascia.

INTRODUCTION

Origin from mammary ridge; middle part of upper third.

INTRODUCTION

Origin from mammary ridge; middle part of upper third.

Boundaries:

Apparently: from 2nd to 6th rib and from lateral sternal border to anterior axillary line.

Actually: from clavicle to below costal margin and from midline to posterior axillary line.

RISK FACTORS:

Hormonal: Estrogen.

RISK FACTORS:

Hormonal: Estrogen.

Cycle numbers “menarche & menopause”

Pregnancy full term.

Lactation 3-4 years.

Obesity.

Exercise.

RISK FACTORS:

Hormonal: Estrogen.

Obesity.

Exercise.

Non-hormonal:

RISK FACTORS:

Hormonal: Estrogen.

Obesity.

Exercise.

Non-hormonal: Radiation:

Ionizing

Mantle radiation (Non-Hodjkin lymphoma”.

RISK FACTORS:

Hormonal:

Estrogen.

Obesity.

Exercise.

Non-hormonal:

Radiation:

Ionizing

Mantle radiation (Non-Hodjkin lymphoma”.

Alcohol.

Fatty diet

Genetic mutations (BRCA-I, BRCA-II)

INCIDENCE:

Every female in USA is born with risk 12%

INCIDENCE:

At age of 50 years risk is 11%

INCIDENCE:

Genetics:

INCIDENCE:

Genetics: BRCA-I mutation risk is 90% to develop cancer breast, 20-40%

cancer ovary.

INCIDENCE:

cancer ovary.

BRCA-II mutation risk is 85% to develop cancer breast.

INCIDENCE:

cancer ovary.

45% of cancer breast patients is found to be +ve for BRCA-I mutation.

INCIDENCE:

cancer ovary.

80% of cancer ovary patients is found to be +ve for BRCA-I mutation.

INCIDENCE:

Genetics: BRCA-I mutation risk is 90% to develop cancer breast, 20-40% cancer

ovary.

80% of cancer ovary patients is found to be +ve for BRCA-I mutation.

So; patient presented with cancer ovary high incidence of BRCA mutation high risk of cancer breast.

BRCA-II mutation

Characterized by: Invasive duct carcinoma.

BRCA-I mutation:

Characterized by: Invasive duct carcinoma (??

medullary)

BRCA-II mutation

Well differentiated.

BRCA-I mutation:

medullary)

Poorly differentiated.

BRCA-II mutation

Express hormonal receptors.

BRCA-I mutation:

medullary)

-ve hormonal receptors.

BRCA-II mutation

Associated malignancies: Cancer stomach, pancreas,

prostate.

BRCA-I mutation:

medullary)

Asssocited tumor risk: Cancer stomach, pancreas,

prostate.

BRCA-II mutation

Associated malignancies: Cancer stomach, pancreas,

prostate.

Cancer G.B., biliary tract and malignant melanoma.

BRCA-I mutation:

medullary)

Asssocited tumor risk: Cancer stomach, pancreas,

prostate.

Cancer cervix, uterus and fallopian tubes.

NATURAL HISTORY OF CANCER BREAST:

Malignant cell repeated doubling.

productive fibrosis ???

desmoplastic response ??? skin retraction.

↑tumor size shedding of malignant cells to intercellular space lymphatics L.N. ++

when cell doubling reach 20th times 3 mm Angiogenic switch “neovascularization” ↑chance of blood spread which is aborted by NK cells and macrophages.

when doubling exceeds 27th times “ 5 mm” successful spread and implantation to ???

with tumor advancement local infiltration of skin lymphatics and skin itself ???

TERMS:

Carcinoma in situ (C.I.S) malignant cells limited to BM. ( ductal or lobular).

TERMS:

Minimal breast cancer C.I.S + invasive carcinoma < 5 mm.

TERMS:

Multicentricity: 2nd tumor in another quadrant “LCIS”.

TERMS:

Multifocality: 2nd tumor in the same quadrant “DCIS”.

TERMS:

Multifocality: 2nd tumor in the same quadrant “DCIS”.

Bilaterality: 15% with DCIS.

60-90% with LCIS.

LCIS & DCIS

LCIS: ♂ or ♀ or both??

DCIS: ♂ or ♀ or both??

LCIS & DCIS

It is just a risk factor.

It is considered the anatomic precursor of invasive duct carcinoma.

LCIS & DCIS

It is just a risk factor.

Subsequent invasive cancer ?? Lobular or ductal ??

It is considered the anatomic precursor of invasive duct carcinoma.

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

NST; axilla 60%

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

NST; axilla 60%

Tubular carcinoma; -ve axilla

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

Medullary; BRCA NST; axilla 60%

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

Medullary; BRCA NST; axilla 60% Mucinous; bulky soft mass

PATHOLOGICAL TYPES:

30 35 40 45 50 55 60 65 70 75 80

Medullary; BRCA NST; axilla 60% Mucinous; bulky soft mass

Tubular carcinoma; -ve axilla Papillary; small mass< 3cm

DIAGNOSIS:

History:

DIAGNOSIS:

History: Mass breast or axillary.

DIAGNOSIS:

Nipple discharge.

DIAGNOSIS:

Nipple discharge.

Nipple deformity.

DIAGNOSIS:

Nipple discharge.

Nipple deformity.

Skin changes.

DIAGNOSIS:

History.

Examination:

DIAGNOSIS:

History.

Examination: patient self examination.

DIAGNOSIS:

History.

Examination: Patient self examination.

Doctor examination.

DIAGNOSIS:

History.

Examination.

Investigations:

DIAGNOSIS:

History.

Examination.

Investigation.

Triple assessment:

DIAGNOSIS:

History.

Examination.

Investigation.

Triple assessment:clinicalimaging: u/s &

mammographybiopsy FNAC, true-cut,

incisional, excisional.

MAMMOGRAPHY:

Dose of X-ray is 4 times the ordinary X-ray.

MAMMOGRAPHY:

Views:

MAMMOGRAPHY:

Views: Craniocaudal (CC)medial parts.

MAMMOGRAPHY:

Mediolateral oblique (MLO) upper outer quadrant and axillary tail.

MAMMOGRAPHY:

Spot compression ± magnification.

MAMMOGRAPHY:

Findings of malignancy:

MAMMOGRAPHY:

Findings of malignancy: Ill defined, irregular, speculated.

MAMMOGRAPHY:

With microcalcifications linear and branched.

MAMMOGRAPHY:

With microcalcifications linear and branched.

± multifocality.

STAGING:

Manchester:

Stage Breast Axilla Arm & supraclavicular

Metastasis

I Mobile mass

---- ---- ----

STAGING:

Manchester:

Metastasis

I Mobile mass

---- ---- ----

II Mobile mass

Mobile axilla

----- ------

STAGING:

Manchester:

Metastasis

I Mobile mass

---- ---- ----

II Mobile mass

Mobile axilla

----- ------

III “locally advanced”

Fixed (skin and/or chest) T4

Fixed axilla ± -------

STAGING:

Manchester:

Metastasis

I Mobile mass

---- ---- ----

II Mobile mass

Mobile axilla

----- ------

III “locally advanced”

Fixed (skin and/or chest) T4

Fixed axilla ± -------

IV “systemic advanced”

T4 Any axilla ± +ve and/orOpposite breast or axilla

TREATMENT:

Stage Breast Axilla Hormonal Chemotherapy

I-II Lumpectomy + RT +ve dissection-ve sentinel LN ??

If +ve ??

TREATMENT:

If +ve ??

III MRM + RT Dissection If +ve +++++

TREATMENT:

If +ve ??

III MRM + RT Dissection If +ve +++++

IV Neo-adjuvantMRM + RT

Dissection If +ve +++++

Thank you

cancer breast overview dr. ehab m.oraby. introduction breast is a modified sweat gland between skin...

years risk

mutation risk

risk factors

cancer breast patients

cancer ovary patients

orabyintroduction breast

pectoral fascia

modified sweat gland

Documents

pectoral muscle segmentation in mammograms based on...

ehab abdelrahman arfeen

mohamed ehab personal portfolio

ehab youssrey abas curriculum vitae

medical image analysiswebsite60s.com › upload › files...

lambou delto pectoral

ehab medhat training portfolio english

pectoral girdle and shoulder

dr ehab cbc

ehab thesis

the breast and pectoral region. the breast the breasts are...

konstantinos chatzikokolakis, ehab elsalamouny,...

pectoral es

tete bayou presentation ehab edits

angor pectoral stabil

4 pectoral region

g04: anterior thoracic wall, breast and lymphatic system ......

function of pectoral ﬁns in rainbow trout: behavioral...

breasts thorax. breasts breast glandular tissue embedded...

excerpts from: the breast - unc radiology...3. normal...